Literature DB >> 25583363

Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.

Cheryse A Furman1, Rebecca A Roof1, Amy E Moritz1, Brittney N Miller1, Trevor B Doyle1, R Benjamin Free1, Ashwini K Banala2, Noel M Paul2, Vivek Kumar2, Christopher D Sibley2, Amy Hauck Newman3, David R Sibley4.   

Abstract

The D3 dopamine receptor represents an important target in drug addiction in that reducing receptor activity may attenuate the self-administration of drugs and/or disrupt drug or cue-induced relapse. Medicinal chemistry efforts have led to the development of D3 preferring antagonists and partial agonists that are >100-fold selective vs. the closely related D2 receptor, as best exemplified by extended-length 4-phenylpiperazine derivatives. Based on the D3 receptor crystal structure, these molecules are known to dock to two sites on the receptor where the 4-phenylpiperazine moiety binds to the orthosteric site and an extended aryl amide moiety docks to a secondary binding pocket. The bivalent nature of the receptor binding of these compounds is believed to contribute to their D3 selectivity. In this study, we examined if such compounds might also be "bitopic" such that their aryl amide moieties act as allosteric modulators to further enhance the affinities of the full-length molecules for the receptor. First, we deconstructed several extended-length D3-selective ligands into fragments, termed "synthons", representing either orthosteric or secondary aryl amide pharmacophores and investigated their effects on D3 receptor binding and function. The orthosteric synthons were found to inhibit radioligand binding and to antagonize dopamine activation of the D3 receptor, albeit with lower affinities than the full-length compounds. Notably, the aryl amide-based synthons had no effect on the affinities or potencies of the orthosteric synthons, nor did they have any effect on receptor activation by dopamine. Additionally, pharmacological investigation of the full-length D3-selective antagonists revealed that these compounds interacted with the D3 receptor in a purely competitive manner. Our data further support that the 4-phenylpiperazine D3-selective antagonists are bivalent and that their enhanced affinity for the D3 receptor is due to binding at both the orthosteric site as well as a secondary binding pocket. Importantly, however, their interactions at the secondary site do not allosterically modulate their binding to the orthosteric site. Published by Elsevier B.V.

Entities:  

Keywords:  Allosteric; Bitopic; Bivalent; D(3) receptor; Dopamine antagonists; Dopamine receptor

Mesh:

Substances:

Year:  2014        PMID: 25583363      PMCID: PMC4449328          DOI: 10.1016/j.euroneuro.2014.11.013

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  38 in total

1.  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.

Authors:  Peter Grundt; Katherine M Prevatt; Jianjing Cao; Michelle Taylor; Christina Z Floresca; Ji-Kyung Choi; Bruce G Jenkins; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2007-08-02       Impact factor: 7.446

Review 2.  Allosteric modulation of G protein-coupled receptors.

Authors:  Lauren T May; Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay Riddle; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

Review 4.  Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.

Authors:  Celine Valant; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Interv       Date:  2009-06

5.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.

Authors:  Peter Grundt; Erin E Carlson; Jianjing Cao; Christina J Bennett; Elizabeth McElveen; Michelle Taylor; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

Review 6.  The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.

Authors:  Frank Boeckler; Peter Gmeiner
Journal:  Pharmacol Ther       Date:  2006-08-14       Impact factor: 12.310

Review 7.  The physiology, signaling, and pharmacology of dopamine receptors.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 8.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

9.  A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.

Authors:  Celine Valant; Karen J Gregory; Nathan E Hall; Peter J Scammells; Michael J Lew; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

10.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  11 in total

Review 1.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

2.  Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective Ligands.

Authors:  James J Sahn; Timothy R Hodges; Jessica Z Chan; Stephen F Martin
Journal:  ChemMedChem       Date:  2016-02-24       Impact factor: 3.466

Review 3.  The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.

Authors:  Mario Rossi; Irene Fasciani; Francesco Marampon; Roberto Maggio; Marco Scarselli
Journal:  Mol Pharmacol       Date:  2017-03-06       Impact factor: 4.436

4.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

5.  Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism.

Authors:  Alessandro Bonifazi; Hideaki Yano; Michael P Ellenberger; Ludovic Muller; Vivek Kumar; Mu-Fa Zou; Ning Sheng Cai; Adrian M Guerrero; Amina S Woods; Lei Shi; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-03-16       Impact factor: 7.446

6.  Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.

Authors:  Vivek Kumar; Alessandro Bonifazi; Michael P Ellenberger; Thomas M Keck; Elie Pommier; Rana Rais; Barbara S Slusher; Eliot Gardner; Zhi-Bing You; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-08-10       Impact factor: 7.446

7.  The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions.

Authors:  Christopher J Draper-Joyce; Ravi Kumar Verma; Mayako Michino; Jeremy Shonberg; Anitha Kopinathan; Carmen Klein Herenbrink; Peter J Scammells; Ben Capuano; Ara M Abramyan; David M Thal; Jonathan A Javitch; Arthur Christopoulos; Lei Shi; J Robert Lane
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

8.  Evaluation of Substituted N-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands.

Authors:  Boeun Lee; Michelle Taylor; Suzy A Griffin; Tamara McInnis; Nathalie Sumien; Robert H Mach; Robert R Luedtke
Journal:  Molecules       Date:  2021-05-26       Impact factor: 4.927

9.  Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Authors:  Mu-Fa Zou; Thomas M Keck; Vivek Kumar; Prashant Donthamsetti; Mayako Michino; Caitlin Burzynski; Catherine Schweppe; Alessandro Bonifazi; R Benjamin Free; David R Sibley; Aaron Janowsky; Lei Shi; Jonathan A Javitch; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-04-01       Impact factor: 7.446

10.  The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.

Authors:  Ravi Kumar Verma; Ara M Abramyan; Mayako Michino; R Benjamin Free; David R Sibley; Jonathan A Javitch; J Robert Lane; Lei Shi
Journal:  PLoS Comput Biol       Date:  2018-01-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.